1
|
Yu R, Luo J, Liu L, Peng X. Hypoglycemic Effect of Edible Fungi Polysaccharides Depends on Their Metabolites from the Fermentation of Human Fecal Microbiota. Foods 2023; 13:97. [PMID: 38201125 PMCID: PMC10778959 DOI: 10.3390/foods13010097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 12/15/2023] [Accepted: 12/25/2023] [Indexed: 01/12/2024] Open
Abstract
Edible fungi polysaccharides are widely sourced and have various physiological activities, including hypoglycemic. Current studies mainly focus on the hypoglycemic activity of polysaccharides themselves, while the strength of the hypoglycemic activity of edible fungi polysaccharides from different sources remained elusive. This study compared the hypoglycemic activity of different edible fungi polysaccharides after in vitro fermentation by fecal bacteria, combined with non-targeted metabolomics and 16S rDNA analysis, to screen out potential key metabolites related to the hypoglycemic activity. The results show that the fermentation supernatants of all four edible fungi polysaccharides significantly increased the glucose consumption and glycogen synthesis of IR-HepG2, also up-regulated the level of hexokinase and down-regulated the level of phosphoenolpyruvate carboxylase. All fermentation supernatants could alleviate the insulin resistance of IR-HepG2 cells by regulating the expression levels of genes related to the IRS-1/PI3K/Akt signaling pathway. Gingerglycolipid A, sphinganine 1-phosphate, matricin, tricarballylic acid, N-carbamoylputrescine, nomega-acetylhistamine, tyramine, and benzamide could be considered as potential key metabolites to evaluate the hypoglycemic effects. Their levels were strongly positively correlated with the abundance of Candidatus_Stoquefichu, Faecalibacterium, Coprococcus, Bacteroides, Eubacterium_ventriosum_group, Anaerostipes, Parabacteroides, and Agathobacter. These metabolites and microorganisms are closely related to the hypoglycemic activity of edible fungi polysaccharides.
Collapse
Affiliation(s)
| | | | | | - Xichun Peng
- Department of Food Science and Engineering, Jinan University, Guangzhou 510632, China
| |
Collapse
|
2
|
Luo M, Zhang Z, Lu Y, Feng W, Wu H, Fan L, Guan B, Dai Y, Tang D, Dong X, Yun C, Hocher B, Liu H, Li Q, Yin L. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease. Int Urol Nephrol 2023; 55:1001-1013. [PMID: 36255506 DOI: 10.1007/s11255-022-03326-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 07/28/2022] [Indexed: 11/28/2022]
Abstract
PURPOSE Diabetic kidney disease (DKD) is the most common complication of type 2 diabetes mellitus (T2DM), and its pathogenesis is not yet fully understood and lacks noninvasive and effective diagnostic biomarkers. In this study, we performed urine metabolomics to identify biomarkers for DKD and to clarify the potential mechanisms associated with disease progression. METHODS We applied a liquid chromatography-mass spectrometry-based metabolomics method combined with bioinformatics analysis to investigate the urine metabolism characteristics of 79 participants, including healthy subjects (n = 20), T2DM patients (n = 20), 39 DKD patients that included 19 DKD with microalbuminuria (DKD + micro) and 20 DKD with macroalbuminuria (DKD + macro). RESULTS Seventeen metabolites were identified between T2DM and DKD that were involved in amino acid, purine, nucleotide and primarily bile acid metabolism. Ultimately, a combined model consisting of 2 metabolites (tyramine and phenylalanylproline) was established, which had optimal diagnostic performance (area under the curve (AUC) = 0.94). We also identified 19 metabolites that were co-expressed within the DKD groups and 41 metabolites specifically expressed in the DKD + macro group. Ingenuity pathway analysis revealed three interaction networks of these 60 metabolites, involving the sirtuin signaling pathway and ferroptosis signaling pathway, as well as the downregulation of organic anion transporter 1, which may be important mechanisms that mediate the progression of DKD. CONCLUSIONS This work reveals the metabolic alterations in T2DM and DKD, constructs a combined model to distinguish them and delivers a novel strategy for studying the underlying mechanism and treatment of DKD.
Collapse
Affiliation(s)
- Maolin Luo
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
- Department of Endocrinology and Metabolism, People's Hospital of Liwan District, Guangzhou, 510380, People's Republic of China
| | - Zeyu Zhang
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
- The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, CN, 518020, People's Republic of China
| | - Yongping Lu
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
| | - Weifeng Feng
- Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, People's Republic of China
| | - Hongwei Wu
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
| | - Lijing Fan
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
| | - Baozhang Guan
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
| | - Yong Dai
- The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, CN, 518020, People's Republic of China
| | - Donge Tang
- The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, CN, 518020, People's Republic of China
| | - Xiangnan Dong
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
| | - Chen Yun
- Department of Nephrology, Charité -Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
| | - Berthold Hocher
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China
- Department of Nephrology, Charité -Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- Department of Medicine Nephrology, University Medicai Centre Mannheim, Heidelberg, Germany
| | - Haiping Liu
- The Second People's Hospital of Lianping County, Guangdong, 517139, People's Republic of China.
| | - Qiang Li
- Dongguan Hospital of Guangzhou University of Traditional Chinese Medicine, Guangdong, 523000, People's Republic of China.
| | - Lianghong Yin
- Department of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510632, China.
| |
Collapse
|
3
|
Carpéné C, Stiliyanov Atanasov K, Les F, Mercader Barcelo J. Hyperglycemia and reduced adiposity of streptozotocin-induced diabetic mice are not alleviated by oral benzylamine supplementation. World J Diabetes 2022; 13:752-764. [PMID: 36188146 PMCID: PMC9521444 DOI: 10.4239/wjd.v13.i9.752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/13/2022] [Accepted: 08/22/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Benzylamine (Bza) oral administration delays the onset of hyperglycemia in insulin-resistant db-/- mice; a genetic model of obesity and type 2 diabetes.
AIM To extend the antihyperglycemic properties of oral benzylamine to a model of insulin-deficient type 1 diabetes.
METHODS Male Swiss mice were rendered diabetic by streptozotocin treatment (STZ) and divided in two groups: one received 0.5% Bza as drinking solution for 24 d (STZ Bza-drinking) while the other was drinking water ad libitum. Similar groups were constituted in age-matched, nondiabetic mice. Food intake, liquid intake, body weight gain and nonfasting blood glucose levels were followed during treatment. At the end of treatment, fasted glycemia, liver and white adipose tissue (WAT) mass were measured, while glucose uptake assays were performed in adipocytes.
RESULTS STZ diabetic mice presented typical features of insulin-deficient diabetes: reduced body mass and increased blood glucose levels. These altered parameters were not normalized in the Bza-drinking group in spite of restored food and water intake. Bza consumption could not reverse the severe fat depot atrophy of STZ diabetic mice. In the nondiabetic mice, no difference was found between control and Bza-drinking mice for any parameter. In isolated adipocytes, hexose uptake was partially activated by 0.1 mmol/L Bza in a manner that was obliterated in vitro by the amine oxidase inhibitor phenelzine and that remained unchanged after Bza supplementation. Oxidation of 0.1 mmol/L Bza in WAT was lower in STZ diabetic than in normoglycemic mice.
CONCLUSION Bza supplementation could not normalize the altered glucose handling of STZ diabetic mice with severe WAT atrophy. Consequently, its antidiabetic potential in obese and diabetic rodents does not apply to lipoatrophic type 1 diabetic mice.
Collapse
Affiliation(s)
- Christian Carpéné
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Toulouse 31432, France
| | - Kristiyan Stiliyanov Atanasov
- Molecular Biology and One Health research group, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma 07122, Spain
| | - Francisco Les
- Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Zaragoza 50830, Spain
| | - Josep Mercader Barcelo
- Molecular Biology and One Health research group, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma 07122, Spain
| |
Collapse
|
4
|
High doses of tyramine stimulate glucose transport in human fat cells. J Physiol Biochem 2022; 78:543-556. [DOI: 10.1007/s13105-021-00864-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 12/09/2021] [Indexed: 01/13/2023]
|
5
|
Carpéné C, Mauriège P, Boulet N, Biron S, Grolleau JL, Garcia-Barrado MJ, Iglesias-Osma MC. Methylamine Activates Glucose Uptake in Human Adipocytes Without Overpassing Action of Insulin or Stimulating its Secretion in Pancreatic Islets. MEDICINES 2019; 6:medicines6030089. [PMID: 31409018 PMCID: PMC6789716 DOI: 10.3390/medicines6030089] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 08/02/2019] [Accepted: 08/07/2019] [Indexed: 12/17/2022]
Abstract
Background: Methylamine, a natural soluble amine present in foods, is known to be a substrate of primary amine oxidase (PrAO) widely expressed in animal tissues. Methylamine has been reported to activate glucose transport in fat cells and to facilitate glucose disposal in rabbits but the interests and limits of such insulin-mimicking actions have not been further explored. This work aimed to perform a preclinical study of the inter-individual variations of these biological properties to study the putative link between PrAO activity and insulin resistance. Methods: Methylamine was tested on human adipocyte preparations and in rabbit pancreatic islets to determine its influence on glucose uptake and insulin release, respectively. PrAO activity and related responses were determined in adipose tissues obtained from two cohorts of non-obese and obese women. Results: Adipose tissue PrAO activity was negatively correlated with insulin resistance in high-risk obese women. PrAO-dependent activation of glucose uptake was negatively correlated with body mass index and reflected the decrease of insulin responsiveness of human fat cells with increasing obesity. Methylamine exhibited antilipolytic properties in adipocytes but was unable to directly activate insulin secretion in isolated pancreatic islets. Conclusions: PrAO activation by its substrates, e.g., methylamine, increases glucose utilization in human adipocytes in a manner that is linked to insulin responsiveness. Methylamine/PrAO interaction can therefore contribute to adipose tissue enlargement but should be considered as potentially useful for diabetes prevention since it could limit lipotoxicity and facilitate glucose handling, at the expense of favoring healthy fat accumulation.
Collapse
Affiliation(s)
- Christian Carpéné
- Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Team 1, 31432 Toulouse, France.
- I2MC, University of Toulouse, UMR1048, Paul Sabatier University, 31432 Toulouse, France.
| | - Pascale Mauriège
- Department of Kinesiology, Faculty of Medicine, Laval University, Québec, QC G1V0A6, Canada
| | - Nathalie Boulet
- Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Team 1, 31432 Toulouse, France
- I2MC, University of Toulouse, UMR1048, Paul Sabatier University, 31432 Toulouse, France
| | - Simon Biron
- Department of Surgery, Faculty of Medicine, Laval University, Québec, QC G1V0A6, Canada
| | | | - Maria José Garcia-Barrado
- Laboratory of Neuroendocrinology, Institute of Neurosciences of Castilla y León (INCyL), University of Salamanca, 37007 Salamanca, Spain
- Laboratory of Neuroendocrinology and Obesity, Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain
- Department of Physiology and Pharmacology, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Mari Carmen Iglesias-Osma
- Laboratory of Neuroendocrinology, Institute of Neurosciences of Castilla y León (INCyL), University of Salamanca, 37007 Salamanca, Spain
- Laboratory of Neuroendocrinology and Obesity, Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain
- Department of Physiology and Pharmacology, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| |
Collapse
|
6
|
Mercader J, Sabater AG, Le Gonidec S, Decaunes P, Chaplin A, Gómez-Zorita S, Milagro FI, Carpéné C. Oral Phenelzine Treatment Mitigates Metabolic Disturbances in Mice Fed a High-Fat Diet. J Pharmacol Exp Ther 2019; 371:555-566. [PMID: 31270215 DOI: 10.1124/jpet.119.259895] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 07/01/2019] [Indexed: 12/15/2022] Open
Abstract
Novel mechanisms and health benefits have been recently suggested for the antidepressant drug phenelzine (PHE), known as a nonselective monoamine oxidase inhibitor. They include an antilipogenic action that could have an impact on excessive fat accumulation and obesity-related metabolic alterations. We evaluated the metabolic effects of an oral PHE treatment on mice fed a high-fat diet (HFD). Eleven-week-old male C57BL/6 mice were fed a HFD and either a 0.028% PHE solution (HFD + PHE) or water to drink for 11 weeks. PHE attenuated the increase in body weight and adiposity without affecting food consumption. Energy efficiency was lower in HFD + PHE mice. Lipid content was reduced in subcutaneous fat pads, liver, and skeletal muscle. In white adipose tissue (WAT), PHE reduced sterol regulatory element-binding protein-1c and phosphoenolpyruvate carboxykinase mRNA levels, inhibited amine-induced lipogenesis, and did not increase lipolysis. Moreover, HFD + PHE mice presented diminished levels of hydrogen peroxide release in subcutaneous WAT and reduced expression of leukocyte transmigration markers and proinflammatory cytokines in visceral WAT and liver. PHE reduced the circulating levels of glycerol, triacylglycerols, high-density lipoprotein cholesterol, and insulin. Insulin resistance was reduced, without affecting glucose levels and glucose tolerance. In contrast, PHE increased rectal temperature and slightly increased energy expenditure. The mitigation of HFD-induced metabolic disturbances points toward a promising role for PHE in obesity treatment and encourages further research on its mechanisms of action. SIGNIFICANCE STATEMENT: Phenelzine reduces body fat, markers of oxidative stress, inflammation, and insulin resistance in high-fat diet mice. Semicarbazide-sensitive amine oxidase, monoamine oxidase, phosphoenolpyruvate carboxykinase, and sterol regulatory element-binding protein-1c are involved in the metabolic effects of phenelzine. Phenelzine could be potentially used for the treatment of obesity-related complications.
Collapse
Affiliation(s)
- Josep Mercader
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Agustín G Sabater
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Sophie Le Gonidec
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Pauline Decaunes
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Alice Chaplin
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Saioa Gómez-Zorita
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Fermín I Milagro
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| | - Christian Carpéné
- Balearic Islands Health Research Institute, Palma de Mallorca, Spain (J.M.); Department of Fundamental Biology and Health Sciences, University of Balearic Islands (UIB), Palma de Mallorca, Spain (J.M.); Alimentómica, S.L., Spin-off from UIB, Palma de Mallorca, Spain (A.G.S.); Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Teams 1 & 3, Toulouse, France (C.C., S.L.G., P.D.); I2MC, University of Toulouse, UMR1048, Paul Sabatier University, Toulouse Cedex 4, France (C.C., S.L.G., P.D.); Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, Ohio (A.C.); Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country and Lucio Lascaray Research Institute, Vitoria, Spain (S.G.-Z.); CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain (S.G.-Z., F.I.M.); Department of Nutrition, Food Science, and Physiology, University of Navarra, Pamplona, Spain (F.I.M.); and Centre for Nutrition Research, University of Navarra, Pamplona, Spain (F.I.M.)
| |
Collapse
|
7
|
Les F, Iffiú-Soltész Z, Mercarder J, Carpéné C. Tyramine activates lipid accumulation in rat adipocytes: influences of <em>in vitro</em> and <em>in vivo</em> administration. AIMS MOLECULAR SCIENCE 2017. [DOI: 10.3934/molsci.2017.3.339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
8
|
Dietary Phenolic Compounds Interfere with the Fate of Hydrogen Peroxide in Human Adipose Tissue but Do Not Directly Inhibit Primary Amine Oxidase Activity. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2016; 2016:2427618. [PMID: 26881018 PMCID: PMC4736399 DOI: 10.1155/2016/2427618] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 11/12/2015] [Indexed: 12/31/2022]
Abstract
Resveratrol has been reported to inhibit monoamine oxidases (MAO). Many substrates or inhibitors of neuronal MAO interact also with other amine oxidases (AO) in peripheral organs, such as semicarbazide-sensitive AO (SSAO), known as primary amine oxidase, absent in neurones, but abundant in adipocytes. We asked whether phenolic compounds (resveratrol, pterostilbene, quercetin, and caffeic acid) behave as MAO and SSAO inhibitors. AO activity was determined in human adipose tissue. Computational docking and glucose uptake assays were performed in 3D models of human AO proteins and in adipocytes, respectively. Phenolic compounds fully inhibited the fluorescent detection of H2O2 generated during MAO and SSAO activation by tyramine and benzylamine. They also quenched H2O2-induced fluorescence in absence of biological material and were unable to abolish the oxidation of radiolabelled tyramine and benzylamine. Thus, phenolic compounds hampered H2O2 detection but did not block AO activity. Only resveratrol and quercetin partially impaired MAO-dependent [(14)C]-tyramine oxidation and behaved as MAO inhibitors. Phenolic compounds counteracted the H2O2-dependent benzylamine-stimulated glucose transport. This indicates that various phenolic compounds block downstream effects of H2O2 produced by biogenic or exogenous amine oxidation without directly inhibiting AO. Phenolic compounds remain of interest regarding their capacity to limit oxidative stress rather than inhibiting AO.
Collapse
|
9
|
High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice. J Physiol Biochem 2015; 72:539-53. [DOI: 10.1007/s13105-015-0456-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 11/26/2015] [Indexed: 01/31/2023]
|
10
|
Carpéné C, Bizou M, Tréguer K, Hasnaoui M, Grès S. Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition. J Physiol Biochem 2015; 71:487-96. [PMID: 25572340 DOI: 10.1007/s13105-014-0379-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Accepted: 12/26/2014] [Indexed: 10/24/2022]
Abstract
Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased plasma monocyte chemoattractant protein-1 (MCP-1) levels). Recently, pioglitazone has been shown to inhibit the B form of monoamine oxidase (MAO) in mouse, while rosiglitazone and troglitazone were described as non-covalent inhibitors of both human MAO A and MAO B. Since molecules interacting with MAO might also inhibit semicarbazide-sensitive amine oxidase (SSAO), known as vascular adhesion protein-1 (VAP-1), and since VAP-1/SSAO inhibitors exhibit anti-inflammatory activity, our aim was to elucidate whether VAP-1/SSAO inhibition could be a mechanism involved in the anti-inflammatory behaviour of glitazones. To this aim, MAO and SSAO activities were measured in human subcutaneous adipose tissue biopsies obtained from overweight women undergoing plastic surgery. The production of hydrogen peroxide, an end-product of amine oxidase activity, was determined in tissue homogenates using a fluorometric method. The oxidation of 1 mM tyramine was inhibited by pargyline and almost resistant to semicarbazide, therefore predominantly MAO-dependent. Rosiglitazone was more potent than pioglitazone in inhibiting tyramine oxidation. By contrast, benzylamine oxidation was only abolished by semicarbazide: hence SSAO-mediated. Pioglitazone hampered SSAO activity only when tested at 1 mM while rosiglitazone was inefficient. However, rosiglitazone exhibited anti-inflammatory activity in human adipocytes by limiting MCP-1 expression. Our observations rule out any involvement of VAP-1/SSAO inhibition and subsequent limitation of leukocyte extravasation in the anti-inflammatory action of glitazones.
Collapse
Affiliation(s)
- Christian Carpéné
- Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale (INSERM U1048), Toulouse, France,
| | | | | | | | | |
Collapse
|
11
|
Januszewski AS, Mason N, Karschimkus CS, Rowley KG, Best JD, O'Neal DN, Jenkins AJ. Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia. Diab Vasc Dis Res 2014; 11:262-269. [PMID: 24853908 DOI: 10.1177/1479164114532963] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE Associations of semicarbazide-sensitive amine oxidase (SSAO) activity with renal and vascular function, oxidative stress, glycaemia and diabetes complications were determined. METHODS Plasma SSAO activity in 94 type 1 diabetes (T1DM) patients, including 34 with microvascular complications T1DM CX[+], and in 96 healthy subjects (CON) was measured by production of benzaldehyde using high-performance liquid chromatography (HPLC). RESULTS SSAO activity (mean ± SD) was greater in T1DM than in CON (1049 ± 294 vs 749 ± 204 mU/L; p < 0.00001) and was higher in T1DM CX[+] vs complication-free DM subjects (1148 ± 313 mU/L vs 982 ± 269 mU/L; p = 0.01). In T1DM, SSAO activity correlated with renal dysfunction [estimated glomerular filtration rate (eGFR): r = -0.44; p = 0.0001; cystatin C: r = 0.47; p = 0.0001] and markers of inflammation [soluble vascular cell adhesion molecule-1 (sVCAM-1): r = 0.41, p = 0.0001; soluble intercellular adhesion molecule-1 (sICAM-1): r = 0.33, p = 0.002] and was inversely related to small artery elasticity (SAE) (r = -0.23, p = 0.03). In CON, SSAO activity correlated with HbA1c (r = 0.26; p = 0.02). CONCLUSION In T1DM, SSAO activity correlates with renal dysfunction, but not with glycaemia, and may promote vascular inflammation and be a therapeutic target.
Collapse
Affiliation(s)
- Andrzej S Januszewski
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - Nick Mason
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - Connie S Karschimkus
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - Kevin G Rowley
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - James D Best
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - David N O'Neal
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| | - Alicia J Jenkins
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
| |
Collapse
|
12
|
Grès S, Bour S, Valet P, Carpéné C. Benzylamine antihyperglycemic effect is abolished by AOC3 gene invalidation in mice but not rescued by semicarbazide-sensitive amine oxidase expression under the control of aP2 promoter. J Physiol Biochem 2012; 68:651-62. [PMID: 22547093 DOI: 10.1007/s13105-012-0171-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2012] [Accepted: 04/10/2012] [Indexed: 12/25/2022]
Abstract
Semicarbazide-sensitive amine oxidase (SSAO) is a transmembrane enzyme that metabolizes primary amines from endogenous or dietary origin. SSAO is highly expressed in adipose, smooth muscle and endothelial cells. In each of these cell types, SSAO is implicated in different biological functions, such as glucose transport activation, extracellular matrix maturation and leucocyte extravasation, respectively. However, the physiological functions of SSAO and their involvement in pathogenesis remain uncompletely characterized. To better understand the role of adipose tissue SSAO, we investigated whether it was necessary and/or sufficient to produce the antihyperglycemic effect of the SSAO-substrate benzylamine, already reported in mice. Therefore, we crossed SSAO-deficient mice invalidated for AOC3 gene and transgenic mice expected to express human SSAO in an adipocyte-specific manner, under the control of aP2 promoter. The aP2-human AOC3 construct (aP2-hAOC3) was equally expressed in the adipose tissue of mice expressing or not the native murine form and almost absent in other tissues. However, the corresponding SSAO activity found in adipose tissue represented only 20 % that of control mice. As a consequence, the benzylamine antihyperglycemic effect observed during glucose tolerance test in control was abolished in AOC3-KO mice but not rescued in mice expressing aP2-hAOC3. The capacity of benzylamine or methylamine to activate glucose uptake in adipocytes exhibited parallel variations in the corresponding genotypes. Although the aP2-hAOC3 construct did not allow a total rescue of SSAO activity in adipose tissue, it could be assessed from our observations that adipocyte SSAO plays a pivotal role in the increased glucose tolerance promoted by pharmacological doses of benzylamine.
Collapse
Affiliation(s)
- Sandra Grès
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1048, I2MC, CHU Rangueil, 31432 Toulouse, France
| | | | | | | |
Collapse
|
13
|
Carpéné C, Desquesnes A, Gomez-Ruiz A, Iffiú-Soltész Z, Le Gonidec S, Mercader J. Long-term activation of semicarbazide-sensitive amine oxidase lowers circulating levels of uric acid in diabetic conditions. Physiol Res 2012; 61:251-7. [PMID: 22480418 DOI: 10.33549/physiolres.932211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Uric acid is involved in nitrogenous waste in animals, together with ammonia and urea. Uric acid has also antioxidant properties and is a surrogate marker of metabolic syndrome. We observed that the elevated plasma uric acid of high-fat fed mice was normalized by benzylamine treatment. Indeed, benzylamine is the reference substrate of semicarbazide-sensitive amine oxidase (SSAO), an enzyme highly expressed in fat depots and vessels, which generates ammonia when catalysing oxidative deamination. Ammonia interferes with uric acid metabolism/solubility. Our aim was therefore to investigate whether the lowering action of benzylamine on uric acid was related to an improvement of diabetic complications, or was connected with SSAO-dependent ammonia production. First, we observed that benzylamine administration lowered plasma uric acid in diabetic db/db mice while it did not modify uric acid levels in normoglycemic and lean mice. In parallel, benzylamine improved the glycemic control in diabetic but not in normoglycemic mice, while plasma urea remained unaltered. Then, uric acid plasma levels were measured in mice invalidated for AOC3 gene, encoding for SSAO. These mice were unable to oxidize benzylamine but were not diabetic and exhibited unaltered plasma uric levels. Therefore, activated or abolished ammonia production by SSAO was without influence on uric acid in the context of normoglycemia. Our observations confirm that plasma uric acid increases with diabetes and can be normalized when glucose tolerance is improved. They also show that uric acid, a multifunctional metabolite at the crossroads of nitrogen waste and of antioxidant defences, can be influenced by SSAO, in a manner apparently related to changes in glucose homeostasis.
Collapse
Affiliation(s)
- C Carpéné
- INSERM U1048 équipe 3, I2MC, Bat. L4, CHU Rangueil, BP 84225, Toulouse Cedex 4, France.
| | | | | | | | | | | |
Collapse
|
14
|
SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med Chem 2011; 2:1735-49. [PMID: 21428797 DOI: 10.4155/fmc.10.260] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Benzylamine exerts insulin-like effects in adipocytes (e.g., glucose uptake and antilipolysis) and improves glucose handling in rodents. RESULTS In murine adipocytes, benzylamine mimics another insulin action: it enhances apelin expression in a manner that is blocked by the semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor semicarbazide. It is shown that in human adipocytes, benzylamine activates glucose transport, but its effects are not additive to maximal insulin stimulation. Benzylamine effects are hydrogen peroxide dependent. They can be reproduced by novel substrates, but not by benzaldehyde. CONCLUSION Owing to the parallelism between the in vitro insulin mimicry and the in vivo improvement of glucose handling elicited by benzylamine in rodents, the SSAO/VAP-1 substrates, with stronger effects on human adipocytes than benzylamine, show promising applications for the treatment of insulin resistance.
Collapse
|
15
|
Dunkel P, Balogh B, Meleddu R, Maccioni E, Gyires K, Mátyus P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 2011; 21:1453-71. [PMID: 21675926 DOI: 10.1517/13543776.2011.594040] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. AREAS COVERED This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 - 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. EXPERT OPINION SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.
Collapse
Affiliation(s)
- Petra Dunkel
- Semmelweis University, Department of Organic Chemistry , Hőgyes Endre utca 7, 1092 Budapest , Hungary
| | | | | | | | | | | |
Collapse
|
16
|
Iffiú-Soltész Z, Mercader J, Daviaud D, Boucher J, Carpéné C. Increased primary amine oxidase expression and activity in white adipose tissue of obese and diabetic db-/- mice. J Neural Transm (Vienna) 2011; 118:1071-7. [PMID: 21298297 DOI: 10.1007/s00702-011-0586-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2010] [Accepted: 01/16/2011] [Indexed: 10/18/2022]
Abstract
The major form of primary amine oxidase expressed in adipose tissue (AT) is encoded by AOC3 gene and is known as semicarbazide-sensitive amine oxidase, identical to vascular adhesion protein-1 (SSAO/VAP-1). Exogenous substrates of SSAO/VAP-1 (e.g. benzylamine) stimulate glucose transport in adipocytes and improve glucose tolerance when injected in diabetic rodents. Numerous reports on the circulating, soluble SSAO/VAP-1 have univocally evidenced an increase in diabetic conditions. However, only scarce studies have investigated whether obesity and/or diabetes is accompanied with variations of AOC3 expression in AT. Therefore, we compared the SSAO/VAP-1 content in different fat depots of db-/- mice (lacking leptin receptor and being hyperphagic, diabetic and obese) and db+/- littermates (normoglycemic and lean). AOC3 expression was increased in perigonadal and subcutaneous AT of db-/- mice, while the maximal velocity of benzylamine oxidation (V (max), expressed as pmoles of hydrogen peroxide produced/min/mg protein) increased only in the latter. Indeed, the relative abundance of primary amine oxidase was increased in subcutaneous AT of db-/- mice at all the levels: mRNA, protein and activity. While considering the overall capacity to oxidise amines contained in each depot, there was an increase in the hypertrophic fat pads of the obese db-/- mice, irrespective of their anatomical location, as a result of their dramatically larger mass than in lean db+/- control. Such higher amount of AT-bound primary amine oxidase warrants further studies to determine whether SSAO/VAP-1 inhibition or activation may be useful in treating metabolic diseases.
Collapse
Affiliation(s)
- Zsuzsa Iffiú-Soltész
- Université de Toulouse, UPS, Institut de Médecine Moléculaire de Rangueil (I2MC), Toulouse, France
| | | | | | | | | |
Collapse
|
17
|
Mercader J, Iffiú-Soltész Z, Bour S, Carpéné C. Oral Administration of Semicarbazide Limits Weight Gain together with Inhibition of Fat Deposition and of Primary Amine Oxidase Activity in Adipose Tissue. J Obes 2011; 2011:475786. [PMID: 21331292 PMCID: PMC3038600 DOI: 10.1155/2011/475786] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Accepted: 12/22/2010] [Indexed: 12/29/2022] Open
Abstract
An enzyme hitherto named semicarbazide-sensitive amine oxidase (SSAO), involved in the oxidation of primary amines, is abundantly expressed in adipocytes. Although SSAO physiological functions remain unclear, several molecules inhibiting its activity have been described to limit fat accumulation in preadipocyte cultures or to reduce body weight gain in obese rodents. Here, we studied whether oral administration of semicarbazide, a prototypical SSAO inhibitor, limits fat deposition in mice. Prolonged treatment with semicarbazide at 0.125% in drinking water limited food and water consumption, hampered weight gain, and deeply impaired fat deposition. The adiposomatic index was reduced by 31%, while body mass was reduced by 15%. Such treatment completely inhibited SSAO, but did not alter MAO activity in white adipose tissue. Consequently, the insulin-like action of the SSAO substrate benzylamine on glucose transport was abolished in adipocytes from semicarbazide-drinking mice, while their insulin sensitivity was not altered. Although semicarbazide is currently considered as a food contaminant with deleterious effects, the SSAO inhibition it induces appears as a novel concept to modulate adipose tissue development, which is promising for antiobesity drug discovery.
Collapse
Affiliation(s)
- Josep Mercader
- Institut National de la Santé et de la Recherche Médicale, INSERM U1048, Equipe 3, 12MC, IFR 150, Bat. L4, CHU Rangueil, BP 84225, 31432 Toulouse Cedex 4, France
- Université Paul Sabatier, 12MC, Centre Hospitalier Universitaire de Rangueil, 31432 Toulouse, France
| | - Zsuzsa Iffiú-Soltész
- Institut National de la Santé et de la Recherche Médicale, INSERM U1048, Equipe 3, 12MC, IFR 150, Bat. L4, CHU Rangueil, BP 84225, 31432 Toulouse Cedex 4, France
- Université Paul Sabatier, 12MC, Centre Hospitalier Universitaire de Rangueil, 31432 Toulouse, France
| | - Sandy Bour
- Université Paul Sabatier, 12MC, Centre Hospitalier Universitaire de Rangueil, 31432 Toulouse, France
| | - Christian Carpéné
- Institut National de la Santé et de la Recherche Médicale, INSERM U1048, Equipe 3, 12MC, IFR 150, Bat. L4, CHU Rangueil, BP 84225, 31432 Toulouse Cedex 4, France
- Université Paul Sabatier, 12MC, Centre Hospitalier Universitaire de Rangueil, 31432 Toulouse, France
- *Christian Carpéné:
| |
Collapse
|
18
|
Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010; 61:355-63. [PMID: 20045461 DOI: 10.1016/j.phrs.2009.12.014] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2009] [Revised: 12/23/2009] [Accepted: 12/23/2009] [Indexed: 12/27/2022]
Abstract
Benzylamine is found in Moringa oleifera, a plant used to treat diabetes in traditional medicine. In mammals, benzylamine is metabolized by semicarbazide-sensitive amine oxidase (SSAO) to benzaldehyde and hydrogen peroxide. This latter product has insulin-mimicking action, and is involved in the effects of benzylamine on human adipocytes: stimulation of glucose transport and inhibition of lipolysis. This study examined whether chronic, oral administration of benzylamine could improve glucose tolerance and the circulating lipid profile without increasing oxidative stress in overweight and pre-diabetic mice. The benzylamine diffusion across the intestine was verified using everted gut sacs. Then, glucose handling and metabolic markers were measured in mice rendered insulin-resistant when fed a high-fat diet (HFD) and receiving or not benzylamine in their drinking water (3600micromol/(kgday)) for 17 weeks. HFD-benzylamine mice showed lower body weight gain, fasting blood glucose, total plasma cholesterol and hyperglycaemic response to glucose load when compared to HFD control. In adipocytes, insulin-induced activation of glucose transport and inhibition of lipolysis remained unchanged. In aorta, benzylamine treatment partially restored the nitrite levels that were reduced by HFD. In liver, lipid peroxidation markers were reduced. Resistin and uric acid, surrogate plasma markers of metabolic syndrome, were decreased. In spite of the putative deleterious nature of the hydrogen peroxide generated during amine oxidation, and in agreement with its in vitro insulin-like actions found on adipocytes, the SSAO-substrate benzylamine could be considered as a potential oral agent to treat metabolic syndrome.
Collapse
|
19
|
Influence of prolonged fasting on monoamine oxidase and semicarbazide-sensitive amine oxidase activities in rat white adipose tissue. J Physiol Biochem 2009; 65:11-23. [PMID: 19588727 DOI: 10.1007/bf03165965] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (SSAO) activities are very high in white adipose tissue (WAT). SSAO, also known as Vascular Adhesion Protein-1 in vessels, is present at the surface of fat cells and independent approaches have evidenced its impressive increase during adipogenesis. However, the factors that might regulate the expression SSAO and MAO in adipose tissue are still poorly defined. Here, we report the influence of fasting on MAO and SSAO activities in adipose depots. A decrease of MAO activity occurred after three days of starvation in the intra-abdominal adipose tissue (INWAT) of male Wistar rats, regardless of their initial adiposity or fat loss. The reduced fat stores of seven-week old rats, loosing 59 % of INWAT mass during fasting, contained only one half of the MAO activity found in fed control. The same reduction of MAO was observed after prolonged fasting in older rats which lose only 26% of their INWAT during the same starvation duration, leading to a fat mass comparable to that of younger fed control rats. It was therefore the endocrine and metabolic changes occurring during fasting that were responsible for the reduced MAO activity and not the amount of INWAT. Surprisingly, SSAO activity remained unchanged during starvation. In subcutaneous WAT, the changes in MAO and SSAO activities exhibited the same tendencies than those found in INWAT. Taken together, these data show that both MAO and SSAO activities increase in INWAT with age-dependent fattening, and indicate that only MAO diminishes during fasting.
Collapse
|
20
|
Yraola F, Zorzano A, Albericio F, Royo M. Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates. ChemMedChem 2009; 4:495-503. [PMID: 19266512 DOI: 10.1002/cmdc.200800393] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) substrates show insulin-mimetic effects and are therefore potentially valuable molecules for the treatment of diabetes mellitus. Herein we review several structural and electronic aspects of SSAO arylalkylamine-based substrates. Two main modifications directly affect amine oxidase (AO) activity: 1) variation in ring substitution modulates the biological activity of the arylalkylamine ligand by converting a substrate into a substrate-like inhibitor, and 2) variation in the number of methylene units between the aromatic ring and the ammonium groups of the arylalkylamine substrates dramatically alters the oxidation rate between species. Furthermore, we review relevant information about mammalian SSAO/VAP-1 substrate selectivity and specificity over monoamine oxidases (MAOs).
Collapse
|
21
|
Roessner V, Weber A, Becker A, Beck G, Frieling H, Bleich S. Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism? Eur J Clin Pharmacol 2007; 63:425-9. [PMID: 17333160 DOI: 10.1007/s00228-007-0272-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2006] [Accepted: 01/22/2007] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Although the treatment of schizophrenia with many second generation antipsychotics is known to be associated with metabolic changes, such as hyperglycemia or hypercholesterolemia, the underlying mechanisms of these adverse reactions remain unclear. In light of the recent focus on the involvement of semicarbazide-sensitive amine oxidase (SSAO) in glucose metabolism, we investigated SSAO serum activity in schizophrenic patients treated with antipsychotics with the objective of determining a possible link between SSAO and impaired glucose metabolism. METHODS Blood samples were drawn from 44 schizophrenic patients (24 receiving second generation antipsychotics known to disturb glucose metabolism) on day 1 and day 5 of inpatient treatment. Forty-one healthy adults with no medical condition known to influence SSAO served as controls. RESULTS Of the 44 schizophrenic patients, the 24 treated with second generation antipsychotics known to disturb glucose metabolism showed significantly lower SSAO serum activity [day 1 (mean +/- SD): 477 +/- 105 mU/L; day 5: 438 +/- 86 mU/L] than the 20 patients treated with other antipsychotics not known to influence glucose metabolism (day 1: 513 +/- 124 mU/L, p = 0.359; day 5: 542 +/- 204 mU/L, p = 0.021) only after 5 days of treatment and compared to healthy controls (526 +/- 142 mU/L, p = 0.021). No differences were observed between schizophrenic patients treated with first generation antipsychotics and the controls. CONCLUSION We found decreased SSAO serum activity exclusively in schizophrenic patients treated with second generation antipsychotics known to disturb glucose metabolism. In terms of the role of SSAO in glucose metabolism, the observed decrease in SSAO serum activity may be linked to metabolic changes that are known to occur in schizophrenic patients being treated with many second generation antipsychotics.
Collapse
Affiliation(s)
- Veit Roessner
- Department of Psychiatry and Psychotherapy, University of Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany.
| | | | | | | | | | | |
Collapse
|
22
|
Wanecq E, Bour S, Verwaerde P, Smih F, Valet P, Carpéné C. Increased monoamine oxidase and semicarbazide-sensitive amine oxidase activities in white adipose tissue of obese dogs fed a high-fat diet. J Physiol Biochem 2007; 62:113-23. [PMID: 17217165 DOI: 10.1007/bf03174072] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Adipocytes express two types of amine oxidases: the cell surface semicarbazide-sensitive amine oxidase (SSAO) and the mitochondrial monoamine oxidase (MAO). In human abdominal subcutaneous adipose tissue, it has been reported that SSAO substrates stimulate glucose transport and inhibit lipolysis while MAO activity is decreased in obese patients when compared to age-matched controls. However, no information has been reported on visceral WAT. To further investigate the obesity-induced regulations of MAO and SSAO in white adipose tissue (WAT) from different anatomical locations, enzyme activities and mRNA abundance have been determined on tissue biopsies from control and high-fat fed dogs, an obesity model already described to be associated with arterial hypertension and hyperinsulinemia. MAO activity was increased in the enlarged omental WAT of diet-induced obese dogs, but not in their mesenteric WAT, another intra-abdominal fat depot. Subcutaneous WAT did not exhibit any change in MAO activity, as did the richest MAO-containing tissue: liver. Similarly, SSAO was increased in omental WAT of diet-induced obese dogs, but was not modified in other WAT and in aorta. The increase in SSAO activity observed in omental WAT likely results from an increased expression of the AOC3 gene since mRNA abundance and maximal benzylamine oxidation velocity were increased. Finally, plasma SSAO was decreased in obese dogs. Although the observed regulations differ from those found in subcutaneous WAT of obese patients, this canine model shows a tissue- and site-specific regulation of peripheral MAO and SSAO in obesity.
Collapse
Affiliation(s)
- E Wanecq
- INSERM U586, IFR 31, Bat. L3, CHU Rangueil, 31432 Toulouse, France
| | | | | | | | | | | |
Collapse
|
23
|
Bour S, Iglesias-Osma MC, Marti L, Duro P, Garcia-Barrado MJ, Pastor MF, Prévot D, Visentin V, Valet P, Moratinos J, Carpéné C. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Eur J Pharmacol 2006; 552:20-30. [PMID: 17056035 DOI: 10.1016/j.ejphar.2006.09.021] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2006] [Revised: 09/07/2006] [Accepted: 09/11/2006] [Indexed: 12/31/2022]
Abstract
Numerous imidazolinic agents exhibit antihyperglycaemic properties and have been described to promote insulin secretion, however their effects on adipose tissue development have been poorly investigated. Since white adipose tissue (WAT) plays an important role in glucose homeostasis and expresses imidazoline (I(2)) binding sites abundantly, this work aimed at studying extrapancreatic actions of two I(2)-site ligands, BU 224 and 2-BFI in adipocytes. Interaction with monoamine oxidase (MAO) was investigated by measuring the ability to modulate [(14)C]tyramine oxidation and hydrogen peroxide production. Direct influence on glucose uptake or on lipolytic activity was tested on mouse, rat, rabbit and human adipocytes. BU 224 and 2-BFI behaved as reversible inhibitors of both MAO-A and -B, as demonstrated by total inhibition of tyramine oxidation in human adipocytes and platelets or in liver from rats previously treated with selective MAO-inhibitors. Moreover, they weakly inhibited semicarbazide-sensitive amine oxidase. Like classical MAO-inhibitors, they were unable to produce hydrogen peroxide and to activate glucose uptake but prevented tyramine to do so in rodent or human adipocytes. BU 224 and 2-BFI also differed from MAO-inhibitors since they inhibited lipolysis at millimolar concentrations via a still undefined pathway independent of alpha(2)-adrenoceptor stimulation, beta-adrenergic antagonism and MAO activation. However, chronic treatment of obese Zucker rats with 2-BFI did not modify the maximal lipolytic capacity or the mild insulin resistance status of their adipocytes. Taken together, our observations demonstrate on WAT novel effects of BU 224 and 2-BFI different from their already reported actions on brain or endocrine pancreas.
Collapse
Affiliation(s)
- Sandy Bour
- Inserm, U586, Unité de Recherches sur les Obésités, Université Paul Sabatier, IFR31, CHU Rangueil, Toulouse, F-31432, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|